Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02574533
Title Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gradalis, Inc.
Indications

melanoma

Therapies

Pembrolizumab

FANG vaccine

Age Groups: adult
Covered Countries USA


No variant requirements are available.